|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 5, 2002; DOI 10.1182/blood-2002-06-1774.
NEOPLASIA
From the Department of Medicine, Division of
Hematology, and the Department of Pathology, Huddinge University
Hospital; the Institute of Environmental Medicine, Division of
Toxicology; and the Department of Medicine, Southern Hospital,
Karolinska Institutet, Stockholm, Sweden.
Low-risk myelodysplastic syndromes (MDS), including refractory
anemia and sideroblastic anemia, are characterized by increased apoptotic death of erythroid progenitors. The signaling pathways that
elicit this pathologic cell death in MDS have, however, remained unclear. Treatment with erythropoietin in combination with granulocyte colony-stimulating factor (G-CSF) may synergistically improve the
anemia in patients with MDS, with a concomitant decrease in the number
of apoptotic bone marrow precursors. Moreover, we have previously
reported that G-CSF inhibits Fas-induced caspase activation in
sideroblastic anemia (RARS). The present data demonstrate that almost
50% of erythroid progenitor cells derived from patients with MDS
exhibit spontaneous release of cytochrome c from
mitochondria with ensuing activation of caspase-9, whereas normal
erythroid progenitors display neither of these features. G-CSF
significantly inhibited cytochrome c release and suppressed
apoptosis, most noticeably in cells from patients with sideroblastic
anemia. Furthermore, inhibition of caspase-9 suppressed both
spontaneous and Fas-mediated apoptosis of erythroid progenitors in all
low-risk MDS cases studied. We propose that the increased sensitivity
of MDS progenitor cells to death receptor stimulation is due to a
constitutive activation of the mitochondrial axis of the apoptotic
signaling pathway in these cells. These studies yield a mechanistic
explanation for the beneficial clinical effects of growth factor
administration in patients with MDS, and provide a model for the study
of growth factor-mediated suppression of apoptosis in other bone
marrow disorders.
(Blood. 2003;101:1080-1086) The myelodysplastic syndromes (MDS) constitute a
heterogeneous group of clonal stem cell disorders characterized by
ineffective hematopoiesis, various degrees of pancytopenia, and a risk
of progression to acute myeloid leukemia.1 Low-risk
myelodysplastic syndromes, including refractory anemia (RA) and RA with
ringed sideroblasts (RARS), are defined as MDS with a low probability of progression to leukemia and with a relatively favorable
outcome.2 Anemia and transfusion dependency are the main
clinical problems for these patients.
Increased apoptosis of bone marrow precursors is a hallmark of
MDS,3-5 and is thought to underlie the ineffective
hematopoiesis evidenced in individuals with MDS. Indeed, apoptosis
mediated via the death receptor, Fas, and its ligand has been suggested to serve as an important pathogenic mechanism in MDS.6-9
However, a clear-cut correlation between the level of expression of
these apoptosis regulators and the degree of bone marrow apoptosis, or
cytopenia, has not been demonstrated. In addition to extrinsic, death
receptor-mediated induction of apoptosis, intrinsic signaling pathways
that depend on mitochondrial events, including the release of
apoptogenic factors such as cytochrome c, also
exist.10,11 Interestingly, signs of mitochondrial
pathology are commonly seen in MDS, including the characteristic
accumulation of iron in the mitochondrial matrix of ringed
sideroblasts,12 as well as the occurrence of mitochondrial
DNA mutations.13,14 However, the potential involvement of
these organelles in apoptosis signaling in MDS has not been evaluated previously.
Recombinant hematopoietic growth factors are frequently used in the
clinical management of patients with MDS to alleviate anemia and
neutropenia. Hence, administration of granulocyte colony-stimulating factor (G-CSF) in combination with erythropoietin (EPO) improves hemoglobin levels in low-risk MDS, with a concomitant decrease in the
number of apoptotic bone marrow precursors.4,15-17
Furthermore, we have shown that G-CSF can inhibit Fas-mediated
apoptosis in RARS, and that G-CSF treatment of CD34+ cells
improves erythroid colony growth in patients with RARS with severe
anemia.18 However, the mechanism underlying the spontaneous apoptosis of MDS bone marrow progenitors, and the protective effect of G-CSF in these cells, has remained elusive. In the
present study, we report for the first time the constitutive mitochondrial release of cytochrome c in MDS progenitor
cells, and show that this event is effectively blocked by G-CSF, thus providing a mechanistic explanation for the beneficial clinical effects
of this growth factor.
Patients and controls
Bone marrow aspiration and MNC cultures
CD34+ cell separation and colony formation assays CD34+ cells were separated from MNCs using the MiniMacs system (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described.18,20 The purity of CD34+ separated cells was assessed by flow cytometry using anti-CD34 monoclonal antibodies (BD Biosciences, San Jose, CA), and was found to be more than 95% in all cases. Phenotype and erythroid maturation were analyzed at days 4, 7, 11, and 14 using CD36 (ImmunoTech, Marseille, France) and GpA (DAKO, Copenhagen, Denmark) antibodies to define immature, early erythroid, and late erythroid cells, respectively, while CD45 was used to define nonerythroid cells.Erythroblast cultures To obtain erythroid progenitor cells of a defined stage of differentiation, we slightly modified a previously described method.21 CD34+ cells were cultured (0.1 × 106/mL) for 14 days in Iscove medium (Sigma, St Louis, MO) supplemented with 15% BIT9500 serum substitute (containing bovine serum albumin, bovine pancreatic insulin, and iron-saturated human transferrin; Stem Cell Technologies, Vancouver, BC, Canada) and recombinant human interleukin 3 (rh-IL-3) (10 ng/mL; PeproTech House, London, England), rh-IL-6 (10 ng/mL; PeproTech House), rh-stem cell factor (rh-SCF; 25ng/ml; Medical & Biological Laboratories), 1% penicillin and streptomycin (Invitrogen, Paisley, Scotland), and 1% L-glutamine (Invitrogen). At day 2 and day 4, medium was replenished as above to sustain the culture at the same cell concentration. Erythropoietin (2 IU/mL; Roche, Basel, Switzerland) was added to the medium at day 7, and fresh medium supplemented as above (plus EPO) was added at days 9 and 11. At day 4, 42% of cells were CD34+CD36 , while 24% were
CD34+CD36+, and 12% were positive only for
CD36 (median values). At day 7, 22% were
CD34+CD36, 14% were
CD34+CD36+, 26% CD36+, and 5%
CD36+GpA+. The median percentages of
CD36+ and GpA+ cells at day 11 were 88% and
61%, respectively, while the corresponding numbers at day 14 were 92%
and 77%. As the present study focused on early erythroid maturation,
we used mainly cells obtained at 0 to 7 days of culture. In addition,
to estimate the presence of ringed sideroblasts, Perls Prussian blue
staining was performed on cytospins prepared at the same timepoints.
However, very few ringed sideroblasts were observed during the 14 days
of erythroblast culture (data not shown).
Caspase activation Caspase-3-like, caspase-8, and caspase-9 activities in hematopoietic progenitor cells were determined at the indicated timepoints using a continuous fluorometric assay modified from Nicholson et al.22 Details of the assay have been described elsewhere.20 Appropriate peptide substrates (Asp-Glu-Val-Asp aminocoumarin [DEVD-AMC], Ile-Glu-Thr-Asp aminocoumarin [IETD-AMC], and Leu-Glu-His-Asp aminocoumarin [LEHD-AMC], respectively) were obtained from Peptide Institute (Osaka, Japan). Data are depicted as picomols AMC release per minute per 106 cells.Cytochrome c release Translocation of cytochrome c from mitochondria to cytosol in hematopoietic stem cells was determined at the indicated timepoints using a previously established method for the concomitant localization of mitochondria and cytochrome c in single cells.23 Briefly, cells were stained with MitoTracker Red CMXRos (Molecular Probes, Eugene, OR), cytocentrifuged onto glass slides, and fixed and permeabilized in paraformaldehyde and Triton X-100. Cells were then stained with an anti-cytochrome c antibody (BD Biosciences), followed by a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (Sigma). Images were analyzed on a Leica DM RXA digital confocal microscope, and further processed using the Slide Book 3.0.9.0 analysis software (Intelligent Imaging, Denver, CO).DNA fragmentation Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL)-based determination of DNA fragmentation was performed according to the manufacturer's instructions (ApopTag; Oncor, Gaithersburg, MD), as previously described.20Statistical analysis Statview 5.0 analysis software (SAS Institute, Cary, NC) was used for analysis of quantitative data. Results are presented as mean values plus or minus SD, or as median values plus ranges, when appropriate. Paired and unpaired t tests were used for comparison of related and unrelated samples. Comparison of 3 groups was made by ANOVA (analysis of variance; factorial measures). P values less than .05 were considered statistically significant.
Spontaneous cytochrome c release in MDS progenitors To explore the role of mitochondria in the ineffective erythroid maturation in MDS we measured release of the mitochondrial intermembrane space protein, cytochrome c, in early erythroblasts from 6 patients with RA (2 RA, of which 1 had 5q , 4 RCMD, of which 3 had 5q), 6 patients with RARS (4 RARS, 2 RCMD-RS),
and 4 normal bone marrows (NBM). Cells were taken from erythroblast cultures at day 4 and day 7 and cytochrome c release was
measured by digital confocal microscopy, with concomitant staining for mitochondria using MitoTracker. As seen in Figure
1A, cytochrome c release
occurred in MDS patient cells, yet was completely absent in NBM.
Cytochrome c release was markedly increased in MDS cells at
day 4 (median, 23%; range, 12%-39%) compared with NBM (median, 1.5%; range, 1%-4%), and increased further at day 7 (median,
35%; range, 15%-64%) (NBM median, 4.5%; range, 4%-5%) (Figure
1B). The increase at day 7 was more pronounced in the RARS cultures (median, 45%; range, 20%-64%). Of note, translocation of
cytochrome c was evident in early (day 4) progenitor cells
that still retained the CD34 antigen, and occurred in the absence of
morphologic signs of mitochondrial iron accumulation (data not shown).
Moreover, DNA fragmentation, as assessed by TUNEL, was undetectable at
this stage (data not shown), thus indicating that the release of
cytochrome c is an early event that precedes nuclear
apoptotic changes.
Mitochondria-dependent signaling in MDS progenitors Pro-caspase-9 is activated in a cytochrome c-dependent manner downstream of mitochondria, and active caspase-9, in turn, cleaves and activates caspase-3.24 To further explore the importance of mitochondrial signaling, we measured caspase-9 activation in MNCs from 9 patients with RA, 12 with RARS, and 6 with NBM. After 18 hours of in vitro culture, spontaneous caspase-9 activity, determined by the hydrolysis of the specific peptide substrate, LEHD-AMC, was almost undetectable in NBM (0.47 ± 0.31 pM AMC/min/105 cells), moderately elevated in RA (1.10 ± 0.37 pM AMC/min/105 cells) and clearly elevated in RARS (1.80 ± 1.20 pM AMC/min/105 cells) (Figure 2A). The difference was significant between RARS and NBM (P = .005), but not between RA and NBM or between RARS and RA. Moreover, spontaneous caspase-3-like activity, determined by DEVD-AMC cleavage, was higher in RARS as compared with NBM (Figure 2B), thus corroborating our previous observations.20 Similar results were now obtained in RA cultures. Hence, in freshly isolated MNCs, DEVDase activity was 5- to 7-fold higher in RARS (1.19 ± 0.96 pM AMC/min/105 cells) and in RA (0.92 ± 0.89 pM AMC/min/105 cells), as compared with NBM (0.18 ± 0.22 pM AMC/min/105 cells) (RARS vs NBM, P = .005 and RA vs NBM, P = .04) (Figure 2B).
We then incubated myelodysplastic and control MNCs in the presence of the irreversible inhibitor of caspase-9, LEHD-fmk (20 µM). A significant reduction of spontaneous caspase-3-like enzyme activation was seen in MDS cultures (P < .0001), as well as in cultures from NBM (P = .02). No significant differences were observed between RA and RARS cultures (Figure 2B). Importantly, LEHD-fmk failed to block Fas-induced cleavage of IETD-AMC, indicative of caspase-8 activity, thus providing evidence for the specificity of this inhibitor (data not shown). These data underscore the importance of mitochondria-dependent signaling for spontaneous apoptosis of bone marrow progenitor cells. We next investigated whether spontaneous caspase-9 activation
negatively affects stem cell proliferation in MDS. For this purpose,
myelodysplastic and normal MNCs were cultured in the presence or
absence of LEHD-fmk, and proliferation was estimated after 24 hours of
incubation. As shown in Figure 3,
proliferation increased in 7 out of 8 patients with RA (mean increase
14.7% ± 13%; P = .07), and in 9 out of 11 patients
with RARS (mean increase 24.3% ± 33%; P = .02). No
significant changes were evident in NBM cultures.
Fas-triggered mitochondrial signaling in MDS We previously showed that low-risk MDS progenitor cells are hypersensitive to Fas ligation.18 To gauge the role of mitochondria in Fas-mediated apoptosis, we assessed caspase-3-like, caspase-8, and caspase-9 activities in MNCs obtained from 10 patients with RA, 12 with RARS, and 10 with NBM. As expected, agonistic anti-Fas antibodies (1 µg/mL) triggered caspase-8, the apical caspase in the death receptor-initiated proteolytic cascade, in both MDS (P < .0001) and NBM cultures (P = .04). Fas ligation also induced caspase-3-like activity in RARS (mean increase 9.3 ± 5; P < .0001) and RA (5.1 ± 2.9; P = .0004) as well as in NBM (1.0 ± 0.7; P = .001). Furthermore, a significant increase in the activation of caspase-9 was seen in RARS (mean increase 1.26 ± 1.06; P = .002) and in RA (1.59 ± 1.32; P = .004) but not in NBM (0.25 ± 0.41; P = .09) (Figure 4A). Importantly, LEHD-fmk significantly reduced caspase-3-like activity in Fas-triggered RARS and RA cells (P = .0003 for both groups) (Figure 4B). Taken together, these data serve as evidence for the involvement of the mitochondrial axis in death receptor (ie, Fas)-induced apoptosis of MDS progenitors.
G-CSF prevents spontaneous and Fas-induced apoptosis in MDS Having established the involvement of mitochondria in both spontaneous and Fas-triggered apoptosis of MDS progenitors, we next analyzed the response of these cells to the recombinant human growth factor, G-CSF. G-CSF (100 ng/mL) significantly reduced apoptosis, determined by the degree of caspase-3-like activity at 4 hours, in Fas-triggered MNCs derived from patients with RARS (P = .004), but not in RA cells (P = .16). After prolonged incubation (8 hours), the antiapoptotic effect of G-CSF was further enhanced in RARS (P = .0005), but this effect remained absent in the RA samples (Figure 5A). G-CSF did not significantly affect apoptosis in NBM cultures (data not shown). Similar results were obtained when cells were probed for Fas-induced caspase-8 activity. Hence, G-CSF significantly reduced IETD-AMC cleavage in RARS (4 hours, P = .002 and 8 hours, P = .0002), while no effect was observed in RA or in NBM. Finally, G-CSF significantly reduced the activation of caspase-9, as evidenced by LEHD-AMC cleavage, in RARS cultures (8 hours, P = .005), whereas no effect was observed in RA cultures (Figure 5B).
In view of the potent inhibition of caspase-9 activity by G-CSF, we then investigated whether G-CSF could prevent cytochrome c release. Indeed, addition of the growth factor drastically inhibited the translocation of cytochrome c in both RA and RARS cultures, at day 4 (early erythroid differentiation) as well as at day 7 (intermediate stage erythroblasts) (Figure 1A,C-D). These data thus indicate that G-CSF exerts its protective effect in MDS progenitors at the level of, or upstream of, mitochondrial release of cytochrome c, with subsequent inhibition of downstream caspases.
Mitochondria are key regulators of apoptosis,10 but the role of these organelles in MDS progenitor cell apoptosis has not been assessed before. In the present study we demonstrate the spontaneous translocation of cytochrome c from mitochondria to cytosol in MDS hematopoietic progenitor cells, and we show that this redistribution of cytochrome c can be prevented by G-CSF. Our previous studies have shown that treatment with EPO alone or in combination with G-CSF yields erythroid improvement in patients with MDS.25 Furthermore, G-CSF is particularly useful in the RARS subgroup, with 50% of patients responding to the combination of growth factors versus only about 10% to EPO alone.15 The current data demonstrate that G-CSF protects against cytochrome c release in early progenitor cells from both sideroblastic and refractory anemia patients. However, the antiapoptotic effect of G-CSF in mononuclear bone marrow cells was significantly more pronounced in patients with RARS, and these findings thus serve as a tentative explanation for the utility of this growth factor in the clinical management of patients with MDS. RARS cells are hypersensitive to ligation of the death receptor, Fas. However, we have shown that inhibitors of Fas signaling fail to prevent spontaneous apoptosis of MDS progenitor cells,20 suggesting that Fas-initiated apoptosis may not be the sole cause of the aberrant apoptosis in RARS. Strong inhibition of spontaneous apoptosis by antagonistic anti-Fas antibodies was observed in one patient with RARS in that study, but we later discovered that the profound anemia at the time of the experiment was due most likely to pneumonia and an activated rheumatoid arthritis, and that the RARS only produced a moderate, non-transfusion-dependent anemia. A recent report verified the increased Fas-sensitivity of CD34+-derived erythroid progenitors in MDS, and showed that an antagonistic Fas-Fc chimeric protein was able to reduce spontaneous apoptosis of these cells.26 However, the MDS subgroup(s) analyzed in that specific study was not disclosed. Thus, it remains possible that Fas-triggering is central in secondary anemia,20,27 and in some, but not all subgroups of MDS.26 Nevertheless, the current data show that inhibition of caspase-9 completely abrogated Fas-triggered activation of caspase-3, thus providing strong evidence that the Fas signal is amplified by, or mediated via, mitochondria in MDS progenitor cells. These findings concur with the previous demonstration of mitochondrial amplification of death receptor signaling both in vitro and in vivo.28-30 Moreover, the existence of mitochondria-dependent signaling pathways may serve to explain the sensitivity of certain cell types to Bcl-2-mediated inhibition of Fas-induced cell death.31 We have provided evidence that erythroid apoptosis in MDS is initiated at the stem cell level, since inhibition of caspase-3, an effector caspase, promoted erythroid colony growth in CD34+ cells derived from patients with MDS.20 In line with these findings, caspase-3 activation was detected in mononuclear bone marrow cells from both RA and RARS patients in the present study. Moreover, striking differences were found between myelodysplastic patients and controls when the percentage of early erythroid progenitors displaying cytochrome c release was analyzed. Hence, cytochrome c release was evident in approximately 50% of the cells in the MDS cultures, while almost no release of cytochrome c could be seen in normal controls. In RA, translocation of cytochrome c was similar in the early stage erythroblasts at day 4 and in the intermediate stage erythroblasts at day 7. In RARS, however, the percentage of cells with cytochrome c release increased from day 4 to day 7, which may correspond to the higher degree of spontaneous caspase-9 activation in the more mature mononuclear cells in this subgroup of patients. We also found that inhibition of caspase-9 reduced the degree of spontaneous caspase-3 activation, and restored proliferation in MDS cultures. Taken together, these findings indicate a critical role for mitochondrial signaling in the spontaneous apoptotic process in low-risk MDS. A classical observation in RARS is the perinuclear clustering of
iron-overloaded mitochondria in so-called ringed sideroblasts (ie,
erythroblasts).32,33 In view of the present findings, it
appears reasonable to speculate that this pathologic pattern of iron
distribution could promote the constitutive release of cytochrome
c. However, such iron-induced damage would have to occur
before iron accumulation is morphologically visible, as very few ringed
sideroblasts developed during the 14 days of erythroblast culture in
the present study. Alternatively, cytochrome c release may
be an early sign of a process that eventually leads to a defect transportation and/or incorporation of iron into hemoglobin. Indeed, previous work has suggested that the key problem in RARS is not a
defect in hemoglobin synthesis, but rather a defect involving mitochondrial iron transport.34 In addition, we also
observed cytochrome c release in RA cultures, including a
conspicuous mitochondrial discharge of cytochrome c in cells
from a patient with 5q It is well known that hematopoietic precursor cells undergo apoptosis upon withdrawal of the relevant CSF.35 Moreover, G-CSF has been shown to block constitutive apoptosis of peripheral blood neutrophils obtained from healthy controls.36,37 More recent studies have disclosed that G-CSF down-regulates Bax expression,38 or alternatively, that G-CSF prevents translocation of Bax to mitochondria in mature neutrophils.39 Similarily, Dewson et al40 have shown that IL-5 prevents the redistribution of Bax and the release of cytochrome c in eosinophils undergoing spontaneous apoptosis. Finally, Villunger et al41 have provided evidence that G-CSF promotes survival of neutrophils largely through a Bcl-2-controlled pathway, that is, through a pathway regulated by the mitochondrion and its associated factors. The latter observations are thus in line with our finding that G-CSF acts at the level of, or upstream of, mitochondrial release of cytochrome c in MDS progenitor cells. The present study is, to the best of our knowledge, the first to provide a potential mechanistic explanation for the antiapoptotic effect of G-CSF in hematopoietic stem cells. To conclude, we provide evidence for intrinsic or
mitochondria-dependent apoptosis in MDS progenitor cells, and show that this aberrant cell death is reversed by G-CSF. As mentioned above, previous studies of MDS cells have documented an increased sensitivity to ligation of death receptors, including Fas and the tumor necrosis factor receptor (TNFR).7,9,42 Indeed, recent
studies have demonstrated an increased sensitivity to tumor
necrosis-related apoptosis-inducing ligand (TRAIL)/APO-2
ligand-mediated apoptosis in MDS, but not in normal bone
marrow.43,44 The current data suggest that this increased
susceptibility to apoptosis is caused by downstream events sensitizing
cells to the receptor-mediated signal. We thus propose a model for
apoptosis in low-risk MDS in which the increased sensitivity to
ligation of death receptors is dependent on constitutive mitochondrial
signaling with ensuing cytochrome c release and downstream
activation of caspase-9 (Figure 6). The
pathogenetic mechanism underlying this hyperactivation of MDS
mitochondria merits further investigation, and such studies may
ultimately provide a key to future, antiapoptotic therapeutic approaches in MDS. The present study may also serve as a paradigm for
the dissection of stem cell apoptosis and growth factor-mediated survival of progenitor cells in other human bone marrow pathologies.
The authors wish to thank Professor Robert Howe (Minnesota University) for reviewing morphology slides according to the World Health Organization classification, and for helpful scientific input. We also thank Professor Sten Orrenius (Karolinska Institutet) for continuous support and illuminating discussions.
Submitted June 14, 2002; accepted August 27, 2002.
Prepublished online as Blood First Edition Paper, September 5, 2002; DOI 10.1182/blood-2002-06-1774.
Supported by grant nos. 3689-B01-07XBC (E.H.L.) and 3820-B01-06XAC (B.Z.) from the Swedish Cancer Society, grant nos. 01:164 (E.H.L.) and 01:188 (B.Z.) from the Stockholm Cancer Society, and grant no. 03X-2471 (B.Z., B.F.) from the Swedish Research Council. B.F. is a Swedish Society for Medical Research scholar.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Eva Hellstrom-Lindberg, Department of Medicine, Division of Hematology, Huddinge University Hospital, Karolinska Institutet, S-141 86 Stockholm, Sweden; e-mail: eva.hellstrom-lindberg{at}medhs.ki.se.
1.
Aul C, Bowen DT, Yoshida Y.
Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.
Haematologica.
1998;83:71-86
2.
Greenberg P, Cox C, LeBeau MM, et al.
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood.
1997;89:2079-2088
3.
Raza A, Gezer S, Mundle S, et al.
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.
Blood.
1995;86:268-276 4. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 1997;21:415-425[CrossRef][Medline] [Order article via Infotrieve]. 5. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. `Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075-1082[CrossRef][Medline] [Order article via Infotrieve]. 6. Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood. 1996;88:1122-1123. 7. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845[CrossRef][Medline] [Order article via Infotrieve]. 8. Lepelley P, Grardel N, Erny O, et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma. 1998;30:307-312[Medline] [Order article via Infotrieve]. 9. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188[CrossRef][Medline] [Order article via Infotrieve].
10.
Green DR, Reed JC.
Mitochondria and apoptosis.
Science.
1998;281:1309-1312 11. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776[CrossRef][Medline] [Order article via Infotrieve]. 12. Bessho F, Ohnishi H, Tabuchi K, Kobayashi M, Hayashi Y. Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 1999;105:149-154[CrossRef][Medline] [Order article via Infotrieve].
13.
Gattermann N, Retzlaff S, Wang YL, et al.
Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia.
Blood.
1997;90:4961-4972 14. Reddy PL, Shetty VT, Dutt D, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol. 2002;116:564-575[CrossRef][Medline] [Order article via Infotrieve].
15.
Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al.
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Blood.
1998;92:68-75
16.
Remacha AF, Arrizabalaga B, Villegas A, et al.
Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Haematologica.
1999;84:1058-1064 17. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000;109:367-375[CrossRef][Medline] [Order article via Infotrieve]. 18. Schmidt-Mende J, Tehranchi R, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia. 2001;15:742-751[CrossRef][Medline] [Order article via Infotrieve]. 19. Jaffe ES,Harris NL,Stein H,Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. 20. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol. 2001;112:714-726[CrossRef][Medline] [Order article via Infotrieve]. 21. Freyssinier JM, Lecoq-Lafon C, Amsellem S, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912-922[CrossRef][Medline] [Order article via Infotrieve]. 22. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43[CrossRef][Medline] [Order article via Infotrieve]. 23. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B. Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene. 2001;20:2877-2888[CrossRef][Medline] [Order article via Infotrieve]. 24. Fadeel B, Orrenius S, Zhivotovsky B. The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia. 2000;14:1514-1525[CrossRef][Medline] [Order article via Infotrieve]. 25. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344-351[CrossRef][Medline] [Order article via Infotrieve]. 26. Claessens Y-E, Bouscary D, Dupont J-M, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594-1601 27. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-252[Medline] [Order article via Infotrieve]. 28. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501[CrossRef][Medline] [Order article via Infotrieve]. 29. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490[CrossRef][Medline] [Order article via Infotrieve]. 30. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400:886-891[CrossRef][Medline] [Order article via Infotrieve]. 31. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. Embo J. 1998;17:1675-1687[CrossRef][Medline] [Order article via Infotrieve]. 32. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199[Medline] [Order article via Infotrieve].
33.
Juneja SK, Imbert M, Sigaux F, Jouault H, Sultan C.
Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes.
J Clin Pathol.
1983;36:566-569 34. May A, de Souza P, Barnes K, Kaaba S, Jacobs A. Erythroblast iron metabolism in sideroblastic marrows. Br J Haematol. 1982;52:611-621[Medline] [Order article via Infotrieve]. 35. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343:76-79[CrossRef][Medline] [Order article via Infotrieve].
36.
Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A.
Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products.
Blood.
1992;80:2012-2020
37.
Brach MA, deVos S, Gruss HJ, Herrmann F.
Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death.
Blood.
1992;80:2920-2924
38.
Dibbert B, Weber M, Nikolaizik WH, et al.
Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation.
Proc Natl Acad Sci U S A.
1999;96:13330-13335
39.
Maianski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW.
Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils.
Blood.
2002;99:672-679
40.
Dewson G, Cohen GM, Wardlaw AJ.
Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils.
Blood.
2001;98:2239-2247
41.
Villunger A, O'Reilly LA, Holler N, Adams J, Strasser A.
Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: regulators of distinct cell death and survival pathways in granulocytes.
J Exp Med.
2000;192:647-658 42. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999;60:36-47[CrossRef][Medline] [Order article via Infotrieve].
43.
Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ.
Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.
Blood.
2001;98:3058-3065 44. Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002;16:67-73[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Hellstrom-Lindberg and M. Cazzola The Role of JAK2 Mutations in RARS and Other MDS Hematology, January 1, 2008; 2008(1): 52 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pellagatti, M. Jadersten, A.-M. Forsblom, H. Cattan, B. Christensson, E. K. Emanuelsson, M. Merup, L. Nilsson, J. Samuelsson, B. Sander, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients PNAS, July 3, 2007; 104(27): 11406 - 11411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pellagatti, M. Cazzola, A. A. N. Giagounidis, L. Malcovati, M. G. D. Porta, S. Killick, L. J. Campbell, L. Wang, C. F. Langford, C. Fidler, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype Blood, July 1, 2006; 108(1): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Solaroglu, J. Cahill, V. Jadhav, and J. H. Zhang A Novel Neuroprotectant Granulocyte-Colony Stimulating Factor Stroke, April 1, 2006; 37(4): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome Blood, February 1, 2006; 107(3): 1156 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma and J. M. Bennett The Myelodysplastic Syndromes: Diagnosis and Treatment Mayo Clin. Proc., January 1, 2006; 81(1): 104 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tehranchi, B. Fadeel, J. Schmidt-Mende, A.-M. Forsblom, E. Emanuelsson, M. Jadersten, B. Christensson, R. Hast, R. B. Howe, J. Samuelsson, et al. Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations Clin. Cancer Res., September 1, 2005; 11(17): 6291 - 6299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jadersten, S. M. Montgomery, I. Dybedal, A. Porwit-MacDonald, and E. Hellstrom-Lindberg Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF Blood, August 1, 2005; 106(3): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tehranchi, R. Invernizzi, A. Grandien, B. Zhivotovsky, B. Fadeel, A.-M. Forsblom, E. Travaglino, J. Samuelsson, R. Hast, L. Nilsson, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes Blood, July 1, 2005; 106(1): 247 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-E. Claessens, S. Park, A. Dubart-Kupperschmitt, V. Mariot, C. Garrido, S. Chretien, F. Dreyfus, C. Lacombe, P. Mayeux, and M. Fontenay Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD Blood, May 15, 2005; 105(10): 4035 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Massullo, L. J. Druhan, B. A. Bunnell, M. G. Hunter, J. M. Robinson, C. B. Marsh, and B. R. Avalos Aberrant subcellular targeting of the G185R neutrophil elastase mutant associated with severe congenital neutropenia induces premature apoptosis of differentiating promyelocytes Blood, May 1, 2005; 105(9): 3397 - 3404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Craven, D. French, W. Ye, F. de Sauvage, and A. Rosenthal Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome Blood, May 1, 2005; 105(9): 3528 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hellstrom-Lindberg Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents Hematology, January 1, 2005; 2005(1): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Howe, A. Porwit-MacDonald, R. Wanat, R. Tehranchi, and E. Hellstrom-Lindberg The WHO classification of MDS does make a difference Blood, May 1, 2004; 103(9): 3265 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Carlsson, A. A. G. Aprikyan, R. Tehranchi, D. C. Dale, A. Porwit, E. Hellstrom-Lindberg, J. Palmblad, J.-I. Henter, and B. Fadeel Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells Blood, May 1, 2004; 103(9): 3355 - 3361. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
and hence its erythrogenic